Background Experimental and clinical data suggest that reducing inflammation without
affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory …

Background High triglyceride levels are associated with increased cardiovascular risk, but
whether reductions in these levels would lower the incidence of cardiovascular events is …

Background Inflammation in the tumour microenvironment mediated by interleukin 1β is
hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did …

Background Inflammation is causally related to atherothrombosis. Treatment with canakinumab,
a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted …

Background Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces
inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is …

… Patients in the CREDENCE trial were enrolled with an eGFR as low as 30 ml/min/1.73 m
2 and continued to be treated with canagliflozin even if their eGFR was below that threshold …

Background Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct
inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is …

Background— Lipoprotein(a) [Lp(a)] is a low-density lipoprotein–like particle largely independent
of known risk factors and predictive of cardiovascular disease. Statins may offset the …

Background: Subclinical inflammation is associated with an increased risk of heart failure
and with adverse prognosis in patients with established heart failure. Yet, treatments …

Aims Canakinumab, a monoclonal antibody targeting interleukin (IL)-1β, reduces rates of
recurrent cardiovascular events without lowering lipids. It is uncertain, however, to what extent …